# Shahneen Sandhu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/shahneen-sandhu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 36,193 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 81 |
| i10-index | 269 |
| Last Known Institution | The University of Melbourne |
| OpenAlex ID | https://openalex.org/A5064026461 |
| ORCID iD | 0000-0002-8660-4475 |
| Works | 645 |

## Researcher papers

Showing 12 of 20.

- [Olaparib for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/olaparib-for-metastatic-castration-resistant-prostate-cancer/)
- [DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer](https://scholariq.org/papers/dna-repair-defects-and-olaparib-in-metastatic-prostate-cancer/)
- [Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma/)
- [Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer](https://scholariq.org/papers/enzalutamide-with-standard-first-line-therapy-in-metastatic-prostate-cancer/)
- [\[177Lu\]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study](https://scholariq.org/papers/177lu-psma-617-radionuclide-treatment-in-patients-with-metastatic-castration/)
- [\[177Lu\]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial](https://scholariq.org/papers/177lu-lu-psma-617-versus-cabazitaxel-in-patients-with-metastatic-castration/)
- [Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study](https://scholariq.org/papers/combination-nivolumab-and-ipilimumab-or-nivolumab-alone-in-melanoma-brain/)
- [Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab](https://scholariq.org/papers/anti-pd-1-therapy-in-patients-with-advanced-melanoma-and-preexisting-autoimmune/)
- [Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/survival-with-olaparib-in-metastatic-castration-resistant-prostate-cancer/)
- [An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer](https://scholariq.org/papers/an-evolutionarily-conserved-function-of-polycomb-silences-the-mhc-class-i/)
- [Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes](https://scholariq.org/papers/dosimetry-of-sup-177-sup-lu-psma-617-in-metastatic-castration-resistant-prostate/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [The University of Melbourne](https://scholariq.org/institutions/the-university-of-melbourne/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.